Characteristics of Pseudomonas aeruginosa isolates from intensive care unit

• Authors: Burcin Ozer , Muserref Tatman-Otkun , Dilek Memis , Metin Otkun
• Languages of publication: EN

Abstracts

EN

The study looked at the antimicrobial resistance patterns, serotypes, molecular types, metallo beta-lactamase, and chromosomal betalactamase enzymes of P. aeruginosa strains isolated from the patients and the staffs of the intensive care unit. P. aeruginosa isolates from the patients as nosocomial pathogens and from the staffs were evaluated for their susceptibilities to the antimicrobials by the disk diffusion and E-test methods. Metallo beta-lactamase enzymes were investigated by E-test, the inducibility of β - lactamase enzymes were detected by the disk antagonism test. Serotyping was performed by slide agglutination method. The P. aeruginosa isolates were typed by pulsed field gel electrophoresis. Twenty-five P. aeruginosa strains from the patients and three from the staffs were isolated. Fifteen P. aeruginosa, eleven of which composed of MDR bacteria, were found in serogroup E, 7 strains in G, 4 strains in B, and 1 strain in serogroup A. In all 12 bacteria in the MDR and serogroup E, metallo beta-lactamase enzyme was found to be positive. And in other 15 strains, except the bacterium which could not be serotyped, chromosomal beta-lactamase was found to be positive. The result of the molecular typing showed PFGE A pattern. In conclusion, a pattern in PFGE which included bacteria from MDR and serogroup E, G which was observed in the P. aeruginosa strains which was isolated from the staff’s hands and from the 5 patients, and PFGE F pattern were found to be observed the most. Finally, the two different clonal strains were found to be established in the intensive care.

Keywords

EN

Pseudomonas aeruginosa; Metallo beta-lactamase; Chromosomal beta-lactamase; Pulsed field gel electrophoresis; Serotypes; Intensive care unit

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2009
• Volume: 4
• Issue: 2
• Pages: 156-163

Dates

published

1 - 6 - 2009

online

27 - 3 - 2009

Contributors

author

Burcin Ozer

• School of Medicine, Department of Microbiology and Clinical Microbiology Hatay, Mustafa Kemal University, 31100, Hatay, Turkey

author

Muserref Tatman-Otkun

• School Of Medicine, Department Of Microbiology And Clinical Microbiology, Trakya University, 22030, Hatay, Turkey

author

Dilek Memis

• School Of Medicine, Department Of Anesthesiology And Reanimation, Trakya University, 22030, Hatay, Turkey

author

Metin Otkun

• School Of Medicine, Department Of Microbiology And Clinical Microbiology, Trakya University, 22030, Hatay, Turkey

References

• [1] Kiska D.L., Gilligan P.H., Pseudomonas, In: Muray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (Eds.), Manual of Clinical Microbiology. 8th ed., ASM Pres, Washington, 2003, 1970–1980
• [2] Pollack M., Pseudomonas aeruginosa, In: Mandell GL, Bennett JE, Dolin R (Eds), Principles and Practice of Infectious Diseases. 4th ed., Churchill Livingstone, New York, 1995, 1980–2003
• [3] Hancock R.E.W., Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria, Clin. Infect. Dis., 1998, 27 (Suppl), 93–99 http://dx.doi.org/10.1086/514909[Crossref]
• [4] Gaynes R.P., Horan T.C., Surveillance of nosocomial infections, In: Mayhall CG (ed), Hospital Epidemiology and Infection Control.1st ed. Lippincott Willams and Wilkins, Philadelphia, 1996, 1017–1037
• [5] Strausbaugh L.J., Sewell D.L., Tjoelker R.C., Heitzman T., Webster T., Ward T. et al., Comparison of three methods for recovery of yeasts from hands of health-care workers, J. Clin. Microbiol., 1996, 34, 471–473
• [6] Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Disk Susceptibility Tests, CLSI document M2-A9, (2006)
• [7] Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Susceptibility Testing, CLSI document M100-S16 (2006)
• [8] Karlowsky J.A., Draghi D.C., Jones M.E., Thornsberry C., Friedland I.R., Sahm D.F., Surveillance for antimicrobial susceptibility among clinical iosalates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2002, Antimicrob. Agents. Chemother., 2003, 47, 1681–1688 http://dx.doi.org/10.1128/AAC.47.5.1681-1688.2003[Crossref]
• [9] Akata F., Otkun M., Teker B., Karabay O., Öğütlü A., Tuğrul M. et al., Frequencies of extended spectrum and chromosomal beta-lactamases in nosocomial gram-negative bacteria, Turkish Journal of Infection, 1997, 11, 256–259
• [10] Goto S., Tsuji A., Oguri T., Kobayashi I., Nishida M., Yabuuchi E., Present situation of serotyping of Pseudomonas aeruginosa in Japan and correlation among three kinds of commercially available serotyping kits, J. Infect. Chemother., 1999, 5: 201–205 http://dx.doi.org/10.1007/s101560050035[Crossref]
• [11] Hernàndez J., Ferrús M.A., Hernàndez M., Owen R.J., Arbitrary primed PCR fingerprinting and serotyping of clinical Pseudomonas aeruginosa strains, FEMS Immun. Med. Microbiol., 1997, 17, 37–47 http://dx.doi.org/10.1016/S0928-8244(96)00103-4[Crossref]
• [12] Speijer H., Savelkoul P.H.M., Bonten M.J., Stobberingh E.E., Tjhie J.H.T., Application of different genotyping methods for Pseudomonas aeruginosa in a setting of endemicity in an intensive care unit, J. Clin. Microbiol., 1999, 37, 3654–3661
• [13] Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., et al., Interpreting Chromosomal DNA restriction patterns produced by Pulsed-Field Gel Electrophoresis: Criteria for bacterial strain typing, J. Clin. Microbiol., 1995, 33, 2233–2239
• [14] Henwood C.J., Livermore D.M., James D., Warner M. and the Pseudomonas study group, Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disk susceptibility test, J. Antimicrob. Chemother., 2001, 47, 789–799 http://dx.doi.org/10.1093/jac/47.6.789[Crossref]
• [15] Swenson J.M., Hindler J.A., Peterson R.L., Antimicrobial agents and susceptibility testing. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (Eds.), Manual of Clinical Microbiology. 8th ed. ASM Pres, Washington, 2003, 1178–1195
• [16] Hall L.M.C., Lıvermore D., Gur D., Akova M., Akalın H.E., OXA-11, an extended-spectrum variant of OXA-10 (PSE-2), beta-lactamase from Pseudomonas aeruginosa, Antimicrob. Agents. Chemother., 1993, 37, 1637–1644
• [17] Walsh T.R., Toleman M.A., Poirel L., and Nordmann P., Metallo-Lactamases: the quiet before the storm? Clin. Microbiol. Rev., 2005, 18, 306–325 http://dx.doi.org/10.1128/CMR.18.2.306-325.2005[Crossref]
• [18] Pournaras S., Maniati M., Petinaki E., Tzouvelekis S., Tsakris A., Legakis N.J. et al., Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4, J. Antimicrob. Chemother., 2003, 51, 1409–1414 http://dx.doi.org/10.1093/jac/dkg239[Crossref]
• [19] Vahaboglu H., Coskunkan F., Tansel O., Oztürk R., Sahin N., Koksal I. et al., Clinical importance of extended-spectrum beta-lactamase (PER-1 type)- producing Acinetobacter spp, and Pseudomonas aeruginosa strains, J. Med. Microbiol., 2001, 50, 642–645
• [20] Lee K., Lee W.G., Uh Y., Ha G.Y., Cho J., Chong Y. et al., VIM and IMP-type metallo-beta-lactamaseproducing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals, Emerg. Infect. Dis., 2003, 9, 868–871 [Crossref]
• [21] Gales A.C., Jones R.N., Turnidge J., Rennie R., Ramphal R., Characterization of Pseudomonas aeruginosa isolates: occurance rates, antimicrobial susceptibility patterns, and molecular typing in the Global SENTRY Antimicrobial Surveillance Program, 1997–1999, Clin. Infect. Dis., 2001, 32(Suppl 2), 146–155 http://dx.doi.org/10.1086/320186[Crossref]
• [22] Shawar R.M., Macleod D.L., Garber R.L., Burns J.L., Stapp J.R., Clausen C.R. et al., Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis, Antimicrob. Agents. Chemother., 1999, 43, 2877–2880
• [23] Wolter D.J., Smith-Moland E., Goering R.V., Hanson N.D., Lister P.D., Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital, Diag. Microbiol. Infec. Dis., 2004, 50, 43–50 http://dx.doi.org/10.1016/j.diagmicrobio.2004.05.004[Crossref]
• [24] The International Pseudomonas aeruginosa Typing Study Group, A multicenter comparison of methods for typing strains of Pseudomonas aeruginosa predominantly from patients with cystic fibrosis, J. Infect. Dis., 1994, 169, 134–142
• [25] Tassios P.T., Gennimata V., Spaliara-Kalogeropoulou L., Kairis D., Koutsia C., Vatopoulos A.C. et al., Multiresistant Pseudomonas aeruginosa serogroup O11 outbreak in an intensive care unit, Clin. Microbiol. Infect., 1997, 3, 621–628 http://dx.doi.org/10.1111/j.1469-0691.1997.tb00468.x[Crossref]
• [26] Vale T.A., Gaston M.A., Pitt T.L., Subdivision of seroypes of Pseudomonas aeruginosa with monoclonal antibodies, J. Clin. Microbiol., 1988, 26, 1779–1782
• [27] Wu Y.L., Scott E.M., Po A.L.W., Tariq V.N., Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa, J. Antimicrob. Chemother., 1999, 44, 389–392 http://dx.doi.org/10.1093/jac/44.3.389[Crossref]

Identifiers

DOI

10.2478/s11536-008-0090-2